series-a
Stage
1
Investors
About
OXCan develops minimally invasive diagnostics for lung diseases by combining high-throughput measurement of the circulating proteome with AI to support clinical decision-making, initially targeting COPD and lung cancer.
Explore OXCan's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.